Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Biomarker</td><td align="left">Biological effect(s) associated with biomarker downregulation</td><td align="center">Reference</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">BAK</td><td align="left">Weak BAK expression in serum of patients with melanoma was associated with lesions presenting “sparse” dermal nests</td><td align="center">[<a href="/journals/drp/2012/156068/#B48">48</a>] </td></tr><tr><td align="center" colspan="3"><hr/></td></tr><tr><td align="left">CIMP (WIF1, TFPI2, RASSF1A, and SOCS1)</td><td align="left">Associated with advancing clinical stage of melanoma</td><td align="center">[<a href="/journals/drp/2012/156068/#B28">28</a>] </td></tr><tr><td align="center" colspan="3"><hr/></td></tr><tr><td align="left">KLOTHO</td><td align="left">Associated with melanoma cell motility and invasiveness</td><td align="center">[<a href="/journals/drp/2012/156068/#B49">49</a>] </td></tr><tr><td align="center" colspan="3"><hr/></td></tr><tr><td align="left">microRNA-211</td><td align="left">Associated with melanoma cells invasiveness</td><td align="center">[<a href="/journals/drp/2012/156068/#B50">50</a>] </td></tr><tr><td align="center" colspan="3"><hr/></td></tr><tr><td align="left">microRNA-29c</td><td align="left">Predicted overall survival in patients with lymph node metastases</td><td align="center">[<a href="/journals/drp/2012/156068/#B27">27</a>]</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Effects of candidate of tumor suppressor biomarkers in melanoma progression.

Dermatology Research and Practice

tab2

Table 2

Table 2: Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases 